RWRui Wei

Rui Wei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rui Wei has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Photo-/electrocatalytic reduction of CO2 based on ferroelectrics

    by Rui Wei, Shun Li, Andy Li, Yuan-Hua Lin

    Converting CO2 into sustainable fuels or useful carbon-derived substances offers an effective strategy for tackling the energy crisis and combating global warming. Photo-/electrocatalytic CO2 reduction provides a simple, energy-efficient, and environmentally friendly route compared to existing technologies. Ferroelectric materials, characterized by their unique spontaneous and switchable polarization, have emerged as promising candidate catalysts due to their controllable surface physical and chemical properties. This review commences by summarizing the mechanism underlying ferroelectric polarization-modulated photo-/electrocatalytic CO2 reduction. We then highlight the recent key advancements in CO2 reduction utilizing ferroelectric materials, along with their performance promotion strategies. Finally, we explore the obstacles and future perspectives in this field. This review will provide useful guidance for systematic design and advancement of effective photo-/electrocatalysts based on ferroelectric materials.


  • Top Cited Papers

    Ultrahigh energy storage in high-entropy ceramic capacitors with polymorphic relaxor phase

    by Min Zhang, Shun Lan, Bing B. Yang, Hao Pan, Yi Q. Liu, Qing H. Zhang, Jun L. Qi, Di Chen, Hang Su, Di Yi, et al.

    Ultrahigh–power-density multilayer ceramic capacitors (MLCCs) are critical components in electrical and electronic systems. However, the realization of a high energy density combined with a high efficiency is a major challenge for practical applications. We propose a high-entropy design in barium titanate (BaTiO 3 )–based lead-free MLCCs with polymorphic relaxor phase. This strategy effectively minimizes hysteresis loss by lowering the domain-switching barriers and enhances the breakdown strength by the high atomic disorder with lattice distortion and grain refining. Benefiting from the synergistic effects, we achieved a high energy density of 20.8 joules per cubic centimeter with an ultrahigh efficiency of 97.5% in the MLCCs. This approach should be universally applicable to designing high-performance dielectrics for energy storage and other related functionalities.


  • PCN21 PATTERNS OF ANGIOGENESIS INHIBITOR TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) IN IRELAND

    by R. McDermott, P. Donnellan, J. McCaffery, F. Keane, S.P. Sarda, C. Korves, A. Luka, R. Wei, M.P. Neary, R. Hanley, et al.

  • Treatment (trx) patterns of angiogenesis inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC) in Ireland.

    by R. S. McDermott, P. P. Donnellan, J. McCaffery, S. P. Sarda, C. Korves, A. Luka, R. Wei, M. Neary, R. Hanley, M. S. Duh

    383 Background: This study evaluated rates of trx modifications and reasons for these changes among pts treated with angiogenesis inhibitors in Irish clinical practice. Methods: Data from medical records were retrospectively reviewed at 3 large oncology centers in Ireland for mRCC pts who were ≥ 18 years and received sunitinib (SU) (n=54), sorafenib (n=9), bevacizumab (n=6), or temsirolimus (n=7) as first-line trx from 1/1/2005 to 8/31/2010. Proportions of pts with trx discontinuation (d/c), interruption, or dose change, and reasons for modifications and time to modifications were determined. Results: Due to small sample sizes in other groups, only results for SU are summarized. 1.9% of pts had prior cytokine therapy. Median first-line trx duration for SU was 8.7 months (mo), while median progression-free survival was 13.8 mo. 87% of patients treated with first-line SU experienced adverse events (AEs); 18.5% experienced grade 3/4 AEs. AEs led to trx modifications in 42.6% of pts. 94.4% of pts started trx on 50 mg QD 4/2 dosing; 33.3% of them were dose reduced to 37.5 mg QD 4/2 with median time to reduction 2.7 mo. Among pts who discontinued trx, 31.6% discontinued within 18 weeks (w) (15.8% within 0-6 w, 7.9% in 7-12 w, and 7.9% in 13-18 w). Among pts who discontinued trx within 18 w, 66.7% discontinued due to AEs. Conclusions: Over three-quarters of SU pts experienced trx modifications, more than half due to AEs. About 24% of txt discontinuations occurred within the first two cycles. This real-world practice study suggests that treatment tolerability is a challenge for physicians in the clinical care of mRCC pts.